Portfolio

Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy

January 16, 2025

Accure Therapeutics, a private translational neuroscience R&D company, today announces the positive results of ACUITY, a phase 2 trial involving a drug candidate that was out-licensed in 2022 to Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (‘Oculis’), a global biopharmaceutical company purpose-driven to save sight and improve eye care.

 

Read more